Avalo Therapeutics, Inc. (AVTX)
NASDAQ·Healthcare·Biotechnology
$12.88
-10.71%
Mkt Cap $162.86M
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 23, 2026 | $59.00K | $59.00K | +0.00% | -$1.54 | -$0.37 | +75.97% | — | — |
| Q4 2025 Nov 6, 2025 | — | — | — | -$1.67 | -$2.19 | -31.14% | — | — |
| Q3 2025 Aug 7, 2025 | — | — | — | -$1.43 | -$1.92 | -34.27% | — | — |
| Q2 2025 May 12, 2025 | — | — | — | -$1.07 | -$1.25 | -16.82% | — | — |
| Q2 2025 Apr 4, 2025 | — | $192.00K | — | $0.58 | -$7.95 | -1470.69% | — | — |
| Q4 2024 Nov 7, 2024 | — | $249.00K | — | -$1.19 | -$2.83 | -137.82% | — | — |
| Q3 2024 Aug 12, 2024 | — | — | — | -$6.70 | -$14.07 | -110.00% | — | — |
| Q3 2024 Jul 11, 2024 | — | — | — | — | -$141.14 | — | — | — |
| Q2 2024 May 13, 2024 | — | $571.00K | — | -$1.18 | -$5.98 | -406.78% | — | — |
| Q4 2023 Nov 9, 2023 | $300.00K | $236.00K | -21.33% | -$261.90 | -$26.19 | +90.00% | — | — |
| Q3 2023 Aug 3, 2023 | $500.00K | $643.00K | +28.60% | -$214.29 | -$140.48 | +34.44% | — | — |
| Q2 2023 May 4, 2023 | $1.00M | $475.00K | -52.50% | -$230.95 | -$202.38 | +12.37% | — | — |
| Q1 2023 Mar 29, 2023 | $3.61M | $896.00K | -75.18% | -$123.81 | -$247.62 | -100.00% | — | — |
| Q4 2022 Nov 7, 2022 | $1.26M | $14.95M | +1088.08% | -$245.24 | $80.95 | +133.01% | — | — |
| Q3 2022 Aug 4, 2022 | $1.19M | $1.03M | -12.94% | -$428.57 | -$328.57 | +23.33% | — | — |
| Q2 2022 May 5, 2022 | $645.50K | $1.17M | +81.72% | -$400.16 | -$571.66 | -42.86% | — | — |
| Q1 2022 Mar 2, 2022 | $1.02M | $219.00K | -78.49% | -$1.90 | -$1.92 | -1.05% | — | — |
| Q4 2021 Nov 9, 2021 | $810.00K | $1.35M | +66.67% | -$543.07 | -$485.91 | +10.53% | — | — |
| Q3 2021 Aug 2, 2021 | $3.35M | $3.35M | +0.00% | -$2.04 | -$2.16 | -5.88% | — | — |
| Q2 2021 May 13, 2021 | $369.69K | $473.00K | +27.95% | -$2.32 | -$3.84 | -65.52% | — | — |